Lopez, JS, Besora, CP, Verge, MM, Joaquin, AB, Recio, SM, Pastor, M, Fierro, JP, Martinez-Esparza, EH, Martinez-Momblan, MA, Majem, M. Non-Pharmacological Dermatologic Care for the Prevention and Management of Immune-Related Skin Toxicities in Patients With Lung Cancer. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Nadal, E, Cantero, A, Paz-Ares, L, Ortega, AL, Barba, A, Iranzo, P, Domine, M, Garcia, J, Blasco, A, Campelo, RG, Rodriguez-Abreu, D, Castro, RL, Vidal, OJ, Tena, I, Diz, P, Provencio, M, Simo, M, Vilariño, N, Navarro,, Bruna, J. NIVIPI-Brain: Phase 2 Study of Nivolumab plus Ipilimumab Combined With Chemotherapy in NSCLC With Synchronous Brain Metastases. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Torresan, S, Torres, CSD, Caramella, C, Ambrosini, P, Gomez-Randulfe, I, Monaca, F, Ribera, A, Goudsmit, A, Michelini, A, Segui, V, Insa, A, Martorell, PM, Romero-Sola, G, Caro-Consuegra, R, Mirallas, O, Priano, I, Valdivia, A, Masfarré, L, Iranzo, P, Martinez-Marti, A, Cedres, S, Catot, S, Sequeira, T, Callejo, A, Bearz, A, Barba, A, Antoñanzas, M, Sais, E, Baena, J, Brandao, M, Mosteiro, M, Vilariño, N, Gambardella, V, Moran, T, Occhipinti, M, Califano, R, Pardo, N, Felip, E, Rocha, P. Histological Transformation as Resistance Mechanism in NSCLC: A Multicenter Study Exploring Clinico-Pathological and Molecular Features. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

De Castro, J, Bernabé, R, Escudero, V, Gutiérrez, F, Majem, M, Gordo, R, Arroyo, I, Arranz, S, Collado, R. Benefits of Adjuvant Alectinib in ALK plus Early-Stage Non-Small Cell Lung Cancer, Recurrences Avoided and Savings for the Spanish Health System. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Provencio, M, Aguiar, D, Antoñanzas, M, Areses, MC, Azkárate, A, Barba, A, Bernabé, R, Blanco, R, Borregon, M, Campos, B, Coves, J, De Castro, J, Domènech, M, Domine, M, Campelo, RG, Gozálvez, CL, Huidobro, G, Insa, A, Juan-Vidal, O, Castro, RL, Martínez-Marti, A, Medina, S, Moreno, MA, Nadal, E, Olivares, A, Reguart, N, Sala, MA, Medina, K, Vilà, L, Massuti, B. ARIAN, Adjuvant Treatment With Sacituzumab and ZimberelimAb in Resected Patients: A Phase III Study-Trial in Progress. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Cappuzzo, F, Zvirbule, Z, Korbenfeld, E, Kolb-Sielecki, J, Isla, D, Sanchez, AYC, Bustillos, A, Herraez-Baranda, L, Barata, T, Young, F, Majem, M. IMscin002 Final Analysis: Patient Preference and Safety of Atezolizumab by Subcutaneous and Intravenous Administration. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Grohé, C, Wu, YL, Tsuboi, M, Majem, M, John, T, Bolanos, A, Taylor, R, Sandelin, M, Herbst, RS. Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Wang, M, Jänne, PA, Doucet, L, Fan, Y, Lv, D, Sun, M, Huang, D, Greillier, L, Planchard, D, Hong, Q, Mazieres, J, Felip, E, Li, X, Hu, Y, Fang, J, Bazhenova, L, Ghiringhelli, F, Dols, MAC, Rodriguez, LPA, Bearz, A, Ferreira, BP, Kim, YJ, Bosch-Barrera, J, Shim, BY, Luo, YH, Tiseo, M, Yang, TY, Carcereny, E, Memmott, R, Zalcman, G, Carpeño, JD, Di Noia, V, Parra, HS, Streich, G, Lee, D, Shum, E, Han, JY, Jaime, JC, Brungs, D, John, T, D'Arcangelo, M, Joaquín, AB, Liu, G, Antonuzzo, L, Fernandez-Hinojal, G, Le, X, Zheng, L, Yang, JCH. A Multinational Phase 2 Randomized Pivotal Study of Sunvozertinib in Pretreated NSCLC With EGFR Exon 20 Insertion Mutations. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Modest, DP, Fakih, M, Salvatore, L, Esaki, T, Lopez-Bravo, DP, Taieb, J, Karamouzis, M, Ruiz-Garcia, E, Kim, TW, Kuboki, Y, Meriggi, F, Cunningham, D, Yeh, KH, Cremolini, C, Tran, Q, Chan, E, Chao, JS, Majer, IM, Pietrantonio, F. Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial. LANCET ONCOLOGY. 2025; 26(9)DOI:10.1016/S1470-2045(25)00352-3. PMID:40812325. IF:35.900(Q1/1D).

Audisio, A, Gallio, C, Velenik, V, Meillat, H, Ruiz-Garcia, E, Riesco, MC, Alecha, JS, Rasschaert, G, Carvalho, C, Randrian, V, Kirac, I, Hernando, J, Artac, M, O'Connor, JM, Waldhorn, I, Braam, PM, Shamseddine, A, Moretto, R, de la Pinta, C, De Felice, F, Dulskas, A, Lopez-Bravo, DP, Vanden Bulcke, A, Bock, F, Deleporte, A, van den Eynde, M, Geboes, KP, Loi, M, Messina, M, Houlze-Laroye, C, Puccini, A, Pastorino, A, Papamichael, D, Fiore, M, Sur, D, Eid, M, Antoun, C, Salati, M, Garajova, I, Jakubauskas, M, Tomasek, J, Pinto, CMS, Schwingel, J, Morano, F, Adams, RA, Dermine, A, Chau, A, Javed, MA, Ghidini, M, Fiorica, F, Montenegro, P, Petrillo, A, Spolverato, G, Margalef, NM, Diaz, M, Baratelli, C, Puleo, F, Karampeazis, A, Sert, F, Gilliaux, Q, De Stefano, A, Liberale, G, Moretti, L, Martinive, P, Thomas, VD, Staggs, V, Saad, ED, Van Laethem, JL, Sclafani, F. Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncology. 2025; 11(9)DOI:10.1001/jamaoncol.2025.2026. PMID:40638097. IF:20.100(Q1/1D).

Alamo, P, López-Laguna, H, Favaro, MTP, Gallardo, A, Alba-Castellon, L, Villaverde, A, Mangues, R, Vázquez, E. Subcutaneous administration of an endocrine-mimetic platform allows for prolonged tumor uptake of a tumor targeting protein. INTERNATIONAL JOURNAL OF PHARMACEUTICS. 2026; 690DOI:10.1016/j.ijpharm.2026.126585. PMID:41521013. IF:5.200(Q1/2D).

Sanchez, JM, Voltà-Durán, E, Parladé, E, Mangues, R, Villaverde, A, Vázquez, E, Unzueta, U. Surpassing protein specificity in biomimetics of bacterial amyloids. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES. 2025; 296DOI:10.1016/j.ijbiomac.2025.139635. PMID:39788253. IF:8.500(Q1/1D).

Voltà-Durán E, Alba-Castellón L, Serna N, Casanova I, López-Laguna H, Gallardo A, Sánchez-Chardi A, Villaverde A, Unzueta U, Vázquez E, Mangues R. High-precision targeting and destruction of cancer-associated PDGFR-ß(+) stromal fibroblasts through self-assembling, protein-only nanoparticles.. Acta Biomaterialia. 2023; 170DOI:10.1016/j.actbio.2023.09.001. PMID:37683965. IF:9.400(Q1/1D).

Hernández-Sánchez, A, Ramiro, AV, Sträng, E, Turki, AT, Abáigar, M, Versluis, J, Thomas, I, Sobas, M, Elicegui, JM, Castellani, G, Benner, A, Azibeiro, R, Tettero, JM, Mecklenbrauck, R, Martínez-López, J, Pratcorona, M, Mills, KI, Sanz, G, Voso, MT, Sören, L, Röllig, C, Thiede, C, Metzeler, KH, Döhner, K, Heuser, M, Haferlach, T, Valk, PJM, Russell, N, Hernández-Rivas, JM, Huntly, B, Ossenkoppele, G, Döhner, H, Bullinger, L. Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study. LEUKEMIA. 2026; 40(2)DOI:10.1038/s41375-025-02851-9. PMID:41535568. IF:13.400(Q1/1D).

Charalampopoulou, S, Ramos-Campoy, S, Duran-Ferrer, M, Puiggros, A, Kamaso, J, Nguyen-Khac, F, Rigolin, GM, Cuneo, A, Collado, R, García-Serra, R, Haferlach, C, Ortega, M, Abrisqueta, P, Bosch, F, Zenz, T, Blanco, ML, Salgado, R, García-Malo, MD, Gimeno, E, Lopez-Guillermo, A, Campo, E, Etter, L, Schoumans, J, Espinet, B, Martin-Subero, JI. Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B-cell-related epigenetic imprinting and genetic alterations. Hemasphere. 2026; 10(1)DOI:10.1002/hem3.70211. PMID:41523081. IF:14.600(Q1/1D).

Torres-Esquius, S, Gabarros-Subira, M, Rivero, ME, López, GR, Mañó, LG, Lopez, F, Fernandez, C, Guijarro, F, Díaz-Beyá, M, Canela, MP, Acha, P, Jáuregui, SN, Tuset, E, Palomo, L, Valcarcel, D, Albareda, FB, Jerez, A, Montoro, MJ. Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults. BLOOD. 2025; 146DOI:10.1182/blood-2025-4998. PMID:. IF:23.100(Q1/1D).

Turki, A, Dall'Olio, D, Carota, L, Polizzi, S, Morote, M, Della Porta, M, Zhao, YM, Lanino, L, Sobas, M, Zhao, YQ, Sanchez, AH, Eric, S, Gimenez, LT, Abáigar, M, Elicegui, JM, Ramiro, AV, Dohner, K, Tettero, J, Esteve, J, Martinez-Lopez, J, Metzeler, K, Haferlach, T, Lehmann, S, Pratcorona, M, Thiede, C, Versluis, J, Mecklenbrauck, R, Heuser, M, Benner, A, Huntley, B, Rivas, JMH, Ossenkoppele, G, Döhner, H, Castellani, G, Bullinger, L. Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia. BLOOD. 2025; 146DOI:10.1182/blood-2025-451. PMID:. IF:23.100(Q1/1D).

Ramil, G, Artigas, A, Giné, A, Oñate, G, Castellet, H, Díaz-Beyá, M, Tormo, M, Cervera, M, Coll, R, Martínez-Serra, J, Vives, S, García-Guiñón, A, Mascaró, M, Gómez, L, García-Avila, S, Vall-Llovera, F, Gómez, R, Arnan, M, Salamero, O, Garrido, A, Esteve, J, Nomdedéu, J, Sierra, J, Pratcorona, M. Comparative analysis of NGS and dPCR for measurable residual disease monitoring in intensively treated acute myeloid leukemia patients. ANNALS OF HEMATOLOGY. 2025; 104(1)DOI:. PMID:. IF:2.400(Q2/5D).

Clavé, S, Montironi, C, Oliveras, G, Varela, M, Catasús, L, Sese, M, Hernández-Gallego, A, Teixido, C, Urbizu, A, González-Vidal, A, Pijuan, L, Sansano, I, Baixeras, N, Vásquez, C, Fuertes, B, Sánchez-Güerri, I, Lopez-Vilaro, L, Mate, JL, Bellosillo, B, Hernández-Losa, J, Muñoz-Mármol, AM. Complementary Role of IHC in ALK Fusion Detection: A Validation Study of NSCLC NGS-Based Screening in Seven Laboratories. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Herrera, IC, Fabregó, IE, Cols, LC, Lladó, MC, Vidal, AG, Martín, LF, Mariscal, IE, Arango, SMR, Metrallé, SCS, Alcañiz, AG. Prognostic significance of genetic biomarkers in glioblastoma IDH wild-type: a retrospective survival analysis. VIRCHOWS ARCHIV. 2025; 487DOI:. PMID:. IF:3.100(Q2/3D).